China Resources Double-Crane Pharmaceutical Co Ltd (600062) Fair Value & Analysis
Healthcare · CN · Market cap 16.8B CNY (≈ $2.5B) · ISIN CNE000000Q94
What is China Resources Double-Crane Pharmaceutical Co Ltd really worth?
A solid business, trading 40% below our fair value of ¥26.84.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 22 days ago
Share price −1.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (¥15.50 to ¥38.69) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥10.47 – ¥33.06 · fair‑value band ¥15.50 – ¥38.69 · the ¥16.02 price screens below the ¥26.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
China Resources Double-Crane Pharmaceutical Co Ltd (600062) currently trades at ¥16.02, while our model-based Fair Value estimate is ¥26.84, implying the stock looks roughly 40.3% undervalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥28.81 per share, and 20 of the 26 models we run sit above the ¥16.02 price. Bear case: the Asset-Based group reads lowest at ¥7.51, and 6 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, China Resources Double-Crane Pharmaceutical Co Ltd generated revenue of 10.7B CNY at a net margin of 15.2%. Revenue declined 8.8% year over year. It earns a return on equity of 13.5%. The balance sheet holds a net cash position of 758M CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥15.50 (bear case) to ¥38.69 (bull case); at ¥16.02, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 68%, 600062 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.7383 per share, which is 2.8 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (¥28.81) versus Asset-Based (¥7.51). Highest evidence: FCF DCF (79).
Notify me when 600062 reaches fair value
Put 600062 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China.
Full company description
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiary of Beijing Pharmaceutical Group Co., Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China Resources Double-Crane Pharmaceutical Co Ltd reported revenue of 11.0B CNY in FY2025 versus 9.1B CNY in FY2021, a compound +4.8%/yr. Reported net income was 1.6B CNY in FY2025, compounding +15.2%/yr from FY2021.
of which total revenue +8.7 % · buybacks/dilution +0.2 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch 600062: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare China Resources Double-Crane Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is China Resources Double-Crane Pharmaceutical Co Ltd (600062) overvalued or undervalued?
What is the fair value of 600062?
What is the quality score of 600062?
What is the revenue of China Resources Double-Crane Pharmaceutical Co Ltd (600062)?
What is the net profit margin of 600062?
Does China Resources Double-Crane Pharmaceutical Co Ltd pay a dividend?
Watch China Resources Double-Crane Pharmaceutical Co Ltd in the live analysis
One click puts China Resources Double-Crane Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.